Journal article

Molecular genetic advances in pituitary tumor development

CJ Yates, KE Lines, RV Thakker

Expert Review of Endocrinology and Metabolism | Published : 2015

Abstract

Pituitary adenomas are a heterogeneous group of tumors that may occur as part of a complex syndrome or as an isolated endocrinopathy and both forms can be familial or non-familial. Studies of syndromic and non-syndromic pituitary adenomas have yielded important insights about the molecular mechanisms underlying tumorigenesis. Thus, syndromic forms, including multiple endocrine neoplasia type 1 (MEN1), MEN4, Carney Complex and McCune Albright syndrome, have been shown to be due to mutations of the tumor-suppressor protein menin, a cyclin-dependent kinase inhibitor (p27Kip1), the protein kinase A regulatory subunit 1-α, and the G-protein α-stimulatory subunit (Gsα), respectively. Non-syndromic..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Medical Research Council


Funding Acknowledgements

This work was supported by the: United Kingdom Medical Research Council (MRC) programme grants (G9825289 and G1000467 to KE Lines and RV Thakker); National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme (to KE Lines and RV Thakker); Royal Australasian College of Physicians Vincent Fairfax Family Foundation Research Fellowship (to CJ Yates); Australia Awards Endeavour Postgraduate Research Fellowship Award (to CJ Yates); Novartis Pharmaceuticals Australia Educational Grant (to CJ Yates); Ipsen Pharmaceuticals Australia Educational Grant (to CJ Yates) and The Unicorn Foundation Educational Grant (to CJ Yates). RV Thakker is a member of an ad hoc panel for Novartis (fees paid to institution); has received lecture fees at a sponsored conference from Novartis, Ipsen, Novo Nordisk and Eli Lilly (fees paid to institution) and is Chairman of AstraZeneca advisory group (fees paid to institution). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.